TuisABUS • NASDAQ
add
Arbutus Biopharma Corp
Vorige sluiting
$3,46
Dagwisseling
$3,45 - $3,53
Jaarwisseling
$1,79 - $4,72
Markkapitalisasie
665,12 m USD
Gemiddelde volume
910,00 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,34 m | -71,25% |
Bedryfskoste | 4,54 m | -22,34% |
Netto inkomste | -19,72 m | 1,92% |
Netto winsgrens | -1,47 k | -241,18% |
Wins per aandeel | -0,14 | 15,57% |
EBITDA | -17,14 m | 18,34% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 127,79 m | -4,76% |
Totale bates | 140,44 m | -11,47% |
Totale aanspreeklikheid | 33,55 m | -14,64% |
Totale ekwiteit | 106,89 m | — |
Uitstaande aandele | 189,49 m | — |
Prys om te bespreek | 6,18 | — |
Opbrengs op bates | -29,07% | — |
Opbrengs op kapitaal | -35,87% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -19,72 m | 1,92% |
Kontant van bedrywe | -20,74 m | 4,81% |
Kontant van beleggings | -11,99 m | -214,93% |
Kontant van finansiering | 1,78 m | 5,59% |
Netto kontantverandering | -30,94 m | -220,11% |
Beskikbare kontantvloei | -10,88 m | 21,66% |
Meer oor
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Gestig
2007
Webwerf
Werknemers
73
